Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Seminar
December 4, 2006
- Chugai, GSK Working to Ensure Stable Supply of Anti-flu Drugs
December 4, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 4, 2006
- BUSINESS NEWS IN BRIEF
December 4, 2006
- OPINION
December 4, 2006
- Taiyo Yakuhin to Do More Business with Multiregional Wholesalers
December 4, 2006
- JMA Confirms Opposition to Insurance Deductible System, Flat Sum Payment for Elderly
December 4, 2006
- 4 Major GE Houses Report Growth in Semiannual Sales, Profits
December 4, 2006
- Improve Healthcare for Elderly Using Consumption Tax: Mr Takemi
December 4, 2006
- Chuikyo Recommends NHI Prices for 17 New Products
December 4, 2006
- Prevention Important for Economy Class Syndrome: GSK Seminar
December 4, 2006
- Price Gaps Between Original and GE Drugs Provide Room for Further Cost Curtailment: Council
December 4, 2006
- Alfresa HD: Reinforced Marketing System Contributes to Strong Growth
December 4, 2006
- Companies Should Be Given Greater Freedom in Pricing New Drugs: Dr Aoki
December 4, 2006
- Industry Exchanges Opinions with Vice Minister of Health
December 4, 2006
- FJPWA Seminar
December 4, 2006
- Mediceo Paltac Holdings Aims for SGA Cost Ratio Below 6%: Mr Kumakura
December 4, 2006
- Drug Wholesaler Business Seminar
December 4, 2006
- Sawai May Consider Comprehensive Alliance with New Drug Makers
November 27, 2006
- Towa Pharmaceutical: Sales Rise 12.2% to \13,324 Mil.
November 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…